MK-3697
Based on 1 Customer Validation
MK-3697 is an orally active orexin 2 receptor (OX2R) antagonist, with an IC50 value of 16 nM and a Ki value of 1.1 nM against human OX2R. MK-3697 blocks the wake-promoting OX2R signaling pathway, reduces active wake time, and increases slow-wave sleep and rapid eye movement sleep time in mice, rats and dogs. MK-3697 can be used for research on insomnia.
For research use only. We do not sell to patients.
- Purity: 98.83%
- CAS No.: 1224846-01-8
- Formula: C23H21N5O3S
- Molecular Weight:447.51
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
Clinical Compound Library
HY-L026
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
|
human OX2R 16 nM (IC50) |
human OX2R 1.1 nM (Ki) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
16 nM
Compound: 24
|
Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of Ala-6,12-orexinA-induced effect after 5 mins by FLIPR assay
Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of Ala-6,12-orexinA-induced effect after 5 mins by FLIPR assay
|
[PMID: 25248679] |
| CHO | IC50 |
1986 nM
Compound: 24
|
Antagonist activity at human OX1R I408V mutant expressed in CHO cells assessed as inhibition of Ala-6,12-orexinA-induced effect after 5 mins by FLIPR assay
Antagonist activity at human OX1R I408V mutant expressed in CHO cells assessed as inhibition of Ala-6,12-orexinA-induced effect after 5 mins by FLIPR assay
|
[PMID: 25248679] |
| Species | Dose | Route | CLplasma | Vdss | T1/2 | AUC0-∞ | Cmax | Tmax | Bioavailability | AUC |
|---|---|---|---|---|---|---|---|---|---|---|
| Rat[1] | 2 mg/kg | i.v. | 40.7 mL/min/kg | 1.2 L/kg | 0.4 h | / | / | / | / | / |
| Rat[1] | 5 mg/kg | p.o. | / | / | / | 3.0 μM·h | 2.1 μM | 0.3 h | 64 % | / |
| Dog[1] | 1 mg/kg | i.v. | 7.2 mL/min/kg | 0.7 L/kg | 1.2 h | / | / | / | / | / |
| Dog[1] | 3 mg/kg | p.o. | / | / | / | 7.5 μM·h | 2.1 μM | 0.7 h | 49 % | / |
| Mice[1] | 100 mg/kg | p.o. | / | / | / | / | 55.3 μM | 2.0 h | / | / |
| Rat[1] | 15 mg/kg | p.o. | / | / | / | / | 5.3 μM | 0.8 h | / | 17.2 μM·h |
| Dog[1] | 3 mg/kg | p.o. | / | / | / | / | 2.7 μM | 1.0 h | / | 9.0 μM·h |
MK-3697 (15 mg/kg; p.o.; single dose) significantly reduces active wake and increases SWS and REM sleep in rats, with unbound plasma concentrations well below the OX1R functional potency threshold[1].
MK-3697 (3 mg/kg; p.o.; single dose) significantly reduces active wake and increases SWS II in dogs within 2 hours of administration, with significant REM sleep effects observed in the subsequent 1.5 hours[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wildtype mice; OX2R-knockout mice[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced active wake by ~30 min/2h compared to vehicle.
Increased slow wave sleep by ~15 min/2h compared to vehicle.
Increased rapid eye movement sleep by ~15 min/2h compared to vehicle.
Ablated sleep-modulating effects in OX2R-knockout mice.
Achieved a plasma Cmax of 55.3 μM and CSF concentration of 4.9 μM at 2 hours post-dose.
-
Animal Model:Rat[1]
-
Dosage:15 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced active wake by ~20 min/2h compared to vehicle.
Increased slow wave sleep by ~15 min/2h compared to vehicle.
Increased rapid eye movement sleep by ~5 min/2h compared to vehicle.
Achieved an AUC of 17.2 μM·h, Tmax of 0.8 hours, plasma Cmax of 5.3 μM, 83.6% plasma protein binding, and unbound plasma Cmax of 0.90 μM.
-
Animal Model:Dog[1]
-
Dosage:3 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced active wake by ~20 min/2h compared to vehicle within 2 hours post-dose.
Increased SWS II by ~20 min/2h compared to vehicle within 2 hours post-dose.
Produced significant REM sleep effects for 1.5 hours after the initial 2-hour post-dose period.
Achieved an AUC of 9.0 μM·h, Tmax of 1.0 hour, plasma Cmax of 2.7 μM, 83.1% plasma protein binding, and unbound plasma Cmax of 0.46 μM.
Chemical Information
-
CAS No. 1224846-01-8
-
Appearance Solid
-
Molecular Weight 447.51
-
Formula C23H21N5O3S
-
Color Light yellow to yellow
-
SMILES
O=C(C1=CC(C2=CC(C)=CN=C2)=NC=C1C3=NC=CS3)NCC4=NC(OC)=C(OC)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
DMSO : 22.5 mg/mL (50.28 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2346 mL | 11.1729 mL | 22.3459 mL | 55.8647 mL |
| 5 mM | 0.4469 mL | 2.2346 mL | 4.4692 mL | 11.1729 mL | |
| 10 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL | 5.5865 mL | |
| 15 mM | 0.1490 mL | 0.7449 mL | 1.4897 mL | 3.7243 mL | |
| 20 mM | 0.1117 mL | 0.5586 mL | 1.1173 mL | 2.7932 mL | |
| 25 mM | 0.0894 mL | 0.4469 mL | 0.8938 mL | 2.2346 mL | |
| 30 mM | 0.0745 mL | 0.3724 mL | 0.7449 mL | 1.8622 mL | |
| 40 mM | 0.0559 mL | 0.2793 mL | 0.5586 mL | 1.3966 mL | |
| 50 mM | 0.0447 mL | 0.2235 mL | 0.4469 mL | 1.1173 mL |
MK-3697 Related Classifications
HY-12301 Related Classifications
Powered by Bioz